» Articles » PMID: 37190033

On the Role of Glycolysis in Early Tumorigenesis-Permissive and Executioner Effects

Overview
Journal Cells
Publisher MDPI
Date 2023 May 16
PMID 37190033
Authors
Affiliations
Soon will be listed here.
Abstract

Reprogramming energy production from mitochondrial respiration to glycolysis is now considered a hallmark of cancer. When tumors grow beyond a certain size they give rise to changes in their microenvironment (e.g., hypoxia, mechanical stress) that are conducive to the upregulation of glycolysis. Over the years, however, it has become clear that glycolysis can also associate with the earliest steps of tumorigenesis. Thus, many of the oncoproteins most commonly involved in tumor initiation and progression upregulate glycolysis. Moreover, in recent years, considerable evidence has been reported suggesting that upregulated glycolysis itself, through its enzymes and/or metabolites, may play a causative role in tumorigenesis, either by acting itself as an oncogenic stimulus or by facilitating the appearance of oncogenic mutations. In fact, several changes induced by upregulated glycolysis have been shown to be involved in tumor initiation and early tumorigenesis: glycolysis-induced chromatin remodeling, inhibition of premature senescence and induction of proliferation, effects on DNA repair, -linked -acetylglucosamine modification of target proteins, antiapoptotic effects, induction of epithelial-mesenchymal transition or autophagy, and induction of angiogenesis. In this article we summarize the evidence that upregulated glycolysis is involved in tumor initiation and, in the following, we propose a mechanistic model aimed at explaining how upregulated glycolysis may play such a role.

Citing Articles

The role of glycolysis in tumorigenesis: From biological aspects to therapeutic opportunities.

Cordani M, Michetti F, Zarrabi A, Zarepour A, Rumio C, Strippoli R Neoplasia. 2024; 58:101076.

PMID: 39476482 PMC: 11555605. DOI: 10.1016/j.neo.2024.101076.


Altered metabolism in cancer: insights into energy pathways and therapeutic targets.

Tufail M, Jiang C, Li N Mol Cancer. 2024; 23(1):203.

PMID: 39294640 PMC: 11409553. DOI: 10.1186/s12943-024-02119-3.


Genomic Deletion of PFKFB3 Decreases In Vivo Tumorigenesis.

Imbert-Fernandez Y, Chang S, Lanceta L, Sanders N, Chesney J, Clem B Cancers (Basel). 2024; 16(13).

PMID: 39001392 PMC: 11240529. DOI: 10.3390/cancers16132330.


Transcriptional regulation and post-translational modifications in the glycolytic pathway for targeted cancer therapy.

Ni X, Lu C, Xu G, Ma J Acta Pharmacol Sin. 2024; 45(8):1533-1555.

PMID: 38622288 PMC: 11272797. DOI: 10.1038/s41401-024-01264-1.


A comprehensive pan-cancer analysis identifies a novel glycolysis score and its hub genes as prognostic and immunological biomarkers.

Zheng D, Long S, Xi M Transl Cancer Res. 2023; 12(10):2852-2874.

PMID: 37969385 PMC: 10643978. DOI: 10.21037/tcr-23-325.


References
1.
Yu L, Chen X, Wang L, Chen S . Oncogenic virus-induced aerobic glycolysis and tumorigenesis. J Cancer. 2018; 9(20):3699-3706. PMC: 6216013. DOI: 10.7150/jca.27279. View

2.
Dai Z, Ramesh V, Locasale J . The evolving metabolic landscape of chromatin biology and epigenetics. Nat Rev Genet. 2020; 21(12):737-753. PMC: 8059378. DOI: 10.1038/s41576-020-0270-8. View

3.
Knudson Jr A . Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A. 1971; 68(4):820-3. PMC: 389051. DOI: 10.1073/pnas.68.4.820. View

4.
Yan S, Zhou N, Zhang D, Zhang K, Zheng W, Bao Y . PFKFB3 Inhibition Attenuates Oxaliplatin-Induced Autophagy and Enhances Its Cytotoxicity in Colon Cancer Cells. Int J Mol Sci. 2019; 20(21). PMC: 6862230. DOI: 10.3390/ijms20215415. View

5.
Camarda R, Zhou A, Kohnz R, Balakrishnan S, Mahieu C, Anderton B . Inhibition of fatty acid oxidation as a therapy for MYC-overexpressing triple-negative breast cancer. Nat Med. 2016; 22(4):427-32. PMC: 4892846. DOI: 10.1038/nm.4055. View